Digital Therapeutic for Schizophrenia
A new smartphone app, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 integrates psychosocial interventions using an adaptive goal-setting technique.
- Phase 3 trial demonstrated reduction in negative symptoms of schizophrenia.
- First experimental prescription digital therapy to show good tolerability and no significant adverse events with antipsychotic treatment.
According to the World Health Organization, an estimated 24 million people worldwide have schizophrenia, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapy CT-155 reduces schizophrenia symptoms.